

12th International Conference on
the Health Effects of Incorporated Radionuclides
Fontenay-aux-Roses, France
October 8 - 11, 2018

Biokinetics of Soluble Plutonium after Wound Injury Treated with Ca-DTPA

Maia Avtandilashvili, Sergei Y. Tolmachev

US Transuranium and Uranium Registries

*College of Pharmacy and Pharmaceutical Sciences,
Washington State University, Richland, WA, USA*

www.ustur.wsu.edu

*“Learning from Plutonium
and Uranium Workers”*



US Transuranium and Uranium Registries



- Follow up **occupationally exposed workers**, from exposure through full lifespan, by studying the biokinetics (uptake, translocation and retention), and tissue dosimetry of the actinides (Pu, Am, and U)




Oct 9, 13:50 pm

The United States Transuranium and Uranium Registries: Fifty-year History of Actinide Biokinetic Research

Motivation


- >2,000 contaminated wounds reported
Commonly treated by tissue excision and chelation
- NCRP 156 Wound Model (2007)
Based exclusively on animal experiments



Motivation

- >2,000 contaminated wounds reported
Commonly treated by tissue excision and chelation
- NCRP 156 Wound Model (2007)
Based exclusively on animal experiments


Soluble material:
Weak
Moderate
Strong
Avid



Motivation

- >2,000 contaminated wounds reported
Commonly treated by tissue excision and chelation
- NCRP 156 Wound Model (2007)
Based exclusively on animal experiments


Colloid



Motivation

- >2,000 contaminated wounds reported
Commonly treated by tissue excision and chelation
- NCRP 156 Wound Model (2007)
Based exclusively on animal experiments


Particle



Motivation


- >2,000 contaminated wounds reported
Commonly treated by tissue excision and chelation
- NCRP 156 Wound Model (2007)
Based exclusively on animal experiments

Fragment



Motivation

- >2,000 contaminated wounds reported
Commonly treated by tissue excision and chelation
- NCRP 156 Wound Model (2007)
Based exclusively on animal experiments





USTUR Data

- 19 cases with ^{239}Pu wound(s) as major intake route
 - 8 whole-body, 11 partial-body
- Chelation treatment administered: 5
- Follow-up bioassay
 - Urine analyses, wound counts
- Post-mortem tissue analyses
 - Liver, skeleton, wound





USTUR Whole-body Donor

- Worked with actinides for 30 years
- ^{239}Pu intake due to contaminated wound
- Treated with Ca-DTPA
- No other significant internal contamination
- Died 40 years post intake at age 87



Accident




- Working in glove box on Pu separation
- Punctured finger on contaminated equipment
- Chemical form reported: $\text{Pu}(\text{NO}_3)_4$
- Hood glove contaminated to $> 40,000$ dpm
- Initial survey meter reading on finger: 20,000 dpm
Decontaminated to $\sim 5,000$ dpm
- Estimated initial ^{239}Pu activity in wound: ~ 4.1 kBq

Treatment

- Contaminated tissue excised twice

A total of 2.3 kBq removed

59 Bq measured in wound a month later



- Chelation therapy with Ca-DTPA

Twice a week over two months


A total of 16 g Ca-DTPA in 18 i.v. injections





Urinalysis Data


- Analysis method: Autoradiography
- MDA: ~ 0.8 mBq
- Valid urine measurements: 83





Urinalysis Data


- Measurements affected by DTPA: 57
- Max excretion rate: 11.2 Bq d⁻¹ on day 1
- Pu activity in urine during treatment: ~~70.5 Bq~~ 77.8 Bq





Urinalysis Data

- Urine measurements not affected by DTPA: 26
- Average excretion rate: 3.0 ± 2.5 mBq d⁻¹
- < MDA after 1,000 days post-intake





Post-mortem Tissue Analysis

Tissue	Concentration, Bq kg ⁻¹	Activity, Bq
<i>Wound</i>		
Right 2 nd finger	n/a	1.35 ± 0.03
Right axillary LN	0.39 ± 0.14	0.0018 ± 0.0006
Skeleton (<i>7 samples</i>)	1.58 ± 0.06	17.5 ± 0.7
Liver	8.5 ± 0.2	12.2 ± 0.3
Lungs	0.088 ± 0.004	0.136 ± 0.007
Thoracic LN	0.18 ± 0.07	0.006 ± 0.002
<i>Other soft tissues</i>		
Kidneys	0.15 ± 0.01	0.041 ± 0.003
Heart	0.20 ± 0.01	0.23 ± 0.01
Brain	0.094 ± 0.005	0.112 ± 0.007





Observations



- Concentration in axillary lymph nodes comparable with other soft tissues
Consistent with intake of soluble material
- Lungs to liver activity ratio $\ll 1$
No significant inhalation intake
- Liver to skeleton activity ratio: 1 : 1.4
Consistent with Leggett et al. Pu systemic model

Methods


- Internal Dosimetry Software IMBA Professional Plus®
Special academic edition
Allows to build and solve the systemic models
- Models applied:
Leggett et al. (2005) Pu Systemic Model
NCRP Wound Model: Strongly retained soluble material





Results: Fit and Predictions

- Maximum likelihood fit of 'baseline' urine data
- χ^2 alpha > 0.05



Pu Retention at Time of Death, Bq

Organ	Predicted	Measured
Liver	10.9	12.2
Skeleton	15.4	17.5
Wound	0	1.4

Bound Pu in wound ??



Results: Intake and Dose

- Intake

IMBA estimate:

Pu excreted with DTPA:


$$\begin{array}{r} 47.6 \text{ Bq} \\ + \\ 77.8 \text{ Bq} \\ \hline 125 \text{ Bq} \end{array}$$

- Committed effective dose

Residual: 24.1 mSv

vs.

Projected: 63.3 mSv





Conclusions


- Data from USTUR whole-body donor used to evaluate wound intake of soluble plutonium
- Forty years post-intake, 12.2 Bq, 17.5 Bq and 1.35 Bq were still retained in this individual's liver, skeleton and wound, respectively
- Initial deposition in wound was estimated to be ~125 Bq of ^{239}Pu ; ~78 Bq was excreted due to Ca-DTPA therapy
- Therapy reduced the effective dose by a factor of 2.6




Future Work

Pu decorporation modeling

- Model DTPA-affected urine data from this case
- Validate and optimize system of models proposed by Dumit *et al.* 2018



Anatomical Regions of Respiratory Tract



Pu bound fraction

- Dissect left lung based on ICRP HRTM compartments: BB, bb, AI
- Measure ^{239}Pu concentrations to evaluate bound Pu in upper airways

Courtesy of W.J. Bair



Questions?

m.avtandilashvili@wsu.edu

www.ustur.wsu.edu